Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the first-line treatment plan independently developed by the company for PD-L1 positive partial recurrence of unresectable or metastatic triple-negative breast cancer has been reviewed by the State Drug Administration for the first-line treatment of EGFR × HER3 dual antibody ADC, Yizekang® (lenkang elontolumab, BL-B01D1/iza-Bren) and PD-1 monoclonal antibodies for PD-L1 positive partial recurrence of unresectable or metastatic triple-negative breast cancer The evaluation center was included in the list of breakthrough treatment varieties, which has recently been publicized. This is the first first-line adaptive breakthrough therapy for a treatment plan related to Yizekang® to be included in the list of breakthrough treatment types by the Drug Review Center.

Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the first-line treatment plan independently developed by the company for PD-L1 positive partial recurrence of unresectable or metastatic triple-negative breast cancer has been reviewed by the State Drug Administration for the first-line treatment of EGFR × HER3 dual antibody ADC, Yizekang® (lenkang elontolumab, BL-B01D1/iza-Bren) and PD-1 monoclonal antibodies for PD-L1 positive partial recurrence of unresectable or metastatic triple-negative breast cancer The evaluation center was included in the list of breakthrough treatment varieties, which has recently been publicized. This is the first first-line adaptive breakthrough therapy for a treatment plan related to Yizekang® to be included in the list of breakthrough treatment types by the Drug Review Center.